Why Glucotrack’s CBGM filing could test the next frontier in diabetes monitoring
Wearable CGMs dominate diabetes care. Glucotrack’s implantable CBGM now faces the harder FDA test: durable blood-based proof.
Why Sequenex’s MedTech Innovator partnership matters for connected device startups
Medtech startups have sensors, but software can slow them down. Sequenex’s MedTech Innovator tie up targets that commercialization gap.
Rezolute’s ersodetug data deepens the congenital hyperinsulinism regulatory debate
Rezolute, Inc. has presented expanded Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, adding continuous glucose monitoring outcomes and open-label extension observations to a program that previously missed its primary endpoint. The update places the late-stage rare disease biotech firm in a complex regulatory position, as the […]
Can Medtronic and Abbott redefine insulin delivery with the Instinct-integrated MiniMed 780G?
Medtronic’s MiniMed 780G now ships in the U.S. with Abbott’s Instinct sensor. Explore how this launch could reshape CGM-insulin system competition.